Antibacterial protein having strong lytic activity to staphylococci including staphylococcus aureus
US-2026035412-A1 · Feb 5, 2026 · US
This page is not indexed by search engines while we improve data quality.
Intron Biotechnology Inc — Cross-Sectional Technologies
Intron Biotechnology Inc holds 50 patents in Cross-Sectional Technologies, with representative filings summarized below.
| Metric | Value |
|---|---|
| Company | Intron Biotechnology Inc |
| Technology | Cross-Sectional Technologies |
| Patents in slice | 50 |
| Recent patents in slice | 9 |
| First year | 2015 |
| Last year | 2026 |
Representative patents
Notable publications linking Intron Biotechnology Inc to Cross-Sectional Technologies.
Antibacterial protein CDL200 having lytic activity against Clostridioides difficile
US-12503494-B2 · Dec 23, 2025 · US
Antibacterial protein having lytic activity to Bacillus genus and method for preparing the same
US-12358953-B2 · Jul 15, 2025 · US
Antibacterial protein having lytic activity to Bacillus genus and method for preparing the same
US-12358953-B2 · Jul 15, 2025 · US
Compositions and methods for inhibiting the proliferation of pathogenic escherichia coli
US-2024366695-A1 · Nov 7, 2024 · US
Recent filings
Latest patents from Intron Biotechnology Inc in Cross-Sectional Technologies.
Antibacterial protein having strong lytic activity to staphylococci including staphylococcus aureus
US-2026035412-A1 · Feb 5, 2026 · US
Antibacterial protein CDL200 having lytic activity against Clostridioides difficile
US-12503494-B2 · Dec 23, 2025 · US
Antibacterial protein having lytic activity to Bacillus genus and method for preparing the same
US-12358953-B2 · Jul 15, 2025 · US
Antibacterial protein having lytic activity to Bacillus genus and method for preparing the same
US-12358953-B2 · Jul 15, 2025 · US
Compositions and methods for inhibiting the proliferation of pathogenic escherichia coli
US-2024366695-A1 · Nov 7, 2024 · US
Related pages
Navigate to parent entity pages.